Financial giants have made a conspicuous bullish move on Cassava Sciences. Our analysis of options history for Cassava Sciences SAVA revealed 14 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $517,107, and 4 were calls, valued at $557,500.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $1.0 and $30.0 for Cassava Sciences, spanning the last three months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Cassava Sciences's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Cassava Sciences's substantial trades, within a strike price spectrum from $1.0 to $30.0 over the preceding 30 days.
Cassava Sciences Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SAVA | CALL | TRADE | BEARISH | 08/16/24 | $25.25 | $22.65 | $23.5 | $1.00 | $430.0K | 0 | 183 |
| SAVA | PUT | SWEEP | BULLISH | 01/17/25 | $9.45 | $8.65 | $9.03 | $17.50 | $93.1K | 417 | 352 |
| SAVA | PUT | SWEEP | BULLISH | 01/17/25 | $9.45 | $8.9 | $9.0 | $17.50 | $85.7K | 417 | 120 |
| SAVA | PUT | TRADE | BEARISH | 02/21/25 | $7.8 | $6.55 | $7.8 | $15.00 | $78.0K | 49 | 0 |
| SAVA | PUT | SWEEP | BEARISH | 01/17/25 | $4.0 | $3.8 | $4.0 | $10.00 | $68.0K | 8.1K | 298 |
About Cassava Sciences
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Current Position of Cassava Sciences
- Currently trading with a volume of 1,801,898, the SAVA's price is down by -6.05%, now at $24.45.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 88 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cassava Sciences with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
